SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton’s tyrosine kinase (BTK) degrader programs, NX-5945 and NX-2127, which are being evaluated in patients with relapsed or refractory B cell malignancies, at 8:30 p.m. PST (11:30 p.m. EST) on Monday, December 11, 2023.

The webcast will feature a presentation by guest speaker Alexey Danilov, M.D., Ph.D., professor, Department of Hematology and Hematopoietic Cell Transplantion, and associate director of the Toni Stephenson Lymphoma Center, City of Hope National Medical Center, who will provide a clinical update on the Phase 1 trial of NX-2127 for which he is a principal investigator. Paula G. O’Connor, M.D., Nurix’s senior vice president of clinical development, will provide a clinical update from Nurix’s ongoing Phase 1 trial of NX-5948.

Webcast details

The live webcast event, which will begin at 8:30 p.m. PST (11:30 p.m. ET) on Monday, December 11, 2023, and the subsequent replay, will be available in the Investors section of the Nurix website under Events and Presentations.

About NX-5948

NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022).

About NX-2127

NX-2127 is a novel bifunctional molecule that degrades BTK and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trial can be accessed at www.clinicaltrials.gov (NCT04830137).

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Forward-Looking Statements

This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding the planned timing for the provision of updates and findings from Nurix’s clinical trials. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions regarding the future of Nurix’s business, its future plans and strategies, its preclinical and clinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the timing and results of Nurix’s preclinical studies and clinical trials; (ii) Nurix’s ability to fund development activities and achieve development goals; (iii) the impact of macroeconomic conditions and global events on Nurix’s business, clinical trials and financial condition; and (v) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2023, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:

Investors
Silinda Neou
Nurix Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.